Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on EUROPEAN WEALTH GROUP LTD. We currently have 5 research reports from 2 professional analysts.
|27Feb17 07:00||RNS||Issue of Equity|
|10Feb17 07:00||RNS||Trading Update|
|17Jan17 07:00||RNS||Issue of Equity|
|18Oct16 07:00||RNS||Change of Adviser|
|07Oct16 11:18||RNS||RESULTS OF FUNDRAISING AND DIRECTORS' DEALINGS|
|07Oct16 07:00||RNS||PROPOSED ACQUISITION OF CERTAIN ASSETS OF TOWRY AM|
|14Sep16 07:00||RNS||Director Dealing|
Frequency of research reports
Research reports on
EUROPEAN WEALTH GROUP LTD
EUROPEAN WEALTH GROUP LTD
Small Cap Breakfast
10 Feb 17
Saffron Energy— Schedule One. Italian Oil and Gas play . Expected admission 24 Feb. Guinness Oil & Gas Exploration—Publication of prospectus. Seeking to raise £50m and invest in 15 exploration companies at launch, with plans to grow the portfolio to 30 positions during its lifetime. Issue closing 23 Feb. Arix Bioscience — Intention to float on the main market from the global healthcare and life science company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
Panmure Morning Note 22-09-15
22 Sep 15
First half revenues of £3.9m were in line with expectations, +90% YOY impacted by an acquisition and +13% like for like. Total AUM rose 30% YOY to £1.08bn. EBITDA in H115 was effectively at break-even level owing to on-going investment in the business but we expect strong growth as EWG expands. We foresee an upgrade to profit forecasts from two further accretive acquisitions made since June. EWG has substantial upside in profits from leveraging up its AUM organically and through consolidation. We remain buyers of the shares for growth with an unchanged SOTP based 140p price target.
Panmure Morning Note 02-07-15
02 Jul 15
European Wealth has made the acquisition of ISM, an UK based IFA, as part of its consolidation strategy. We will lift our forecasts for the expected accretion from the deal. The shares trade on c12x FY16 earnings post this deal. We remain on a Buy recommendation with a 140p target price.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
Industry fundamentals remain positive
21 Feb 17
The Biotech Growth Trust (BIOG) is a specialist vehicle, aiming to generate long-term capital growth via investment in global biotech stocks. Following a particularly volatile period for the biotech industry, where concerns about drug pricing and investor risk aversion have weighed heavily on stock prices, the managers are hopeful that greater clarity regarding US healthcare policy will lead to continued improved performance of biotech stocks. Industry fundamentals remain attractive, including continued innovation and valuations are very supportive, which offers the potential for higher industry merger and acquisition activity.
Lloyds, Best Of The Banks
23 Feb 17
Lloyds Banking Group PLC (LLOY) reported a strong result for FY-16, which has allowed it to pay a special dividend, plus has encouraged the UK government to reduce its stake in the bank to below 5%. Lloyds’ acquisition of the MBNA credit card business is proceeding on track, with all key M&A metrics being well satisfied. The outlook for Lloyds’ capital base, its profitability and thus the dividend prospects have all improved. This encourages us to ascribe a Buy rating to the stock, with a target price of 80p per share, derived from a prospective Price / Book value of 1.3x and a P/E ratio of 13x which we think are justifiable ratios.
Marked confidence in profitability resilience
22 Feb 17
LBG posted a good set of results at the operating level. Management showed its confidence in the group’s ability to protect its indecent profitability levels over the next three years by recommending an increased ordinary dividend and the payment of a special dividend, and by setting a stable return on required equity objectives.
Middle Britain growth
21 Feb 17
The Company has achieved our 2017 estimate in 2016 with EBITDA of £2.2m, up 37% on 2015. We upgrade our estimates by 10% at the EBITDA level in 2017. If the shares traded even at the lower end of comparators, they would trade at 17p. We expect the share price to reach our upgraded 17p price target in the short term. Few companies enjoy the unique positioning which Lighthouse has to benefit from the assets of Middle Britain.
Accelerated non-core assets rundown
23 Feb 17
The quarterly results were depressed by some one-offs or seasonal charges and by the costs associated with the accelerated run-down of non-core assets. The underlying profitability remained remarkably stable at a decent 11% ROTE. The regulatory capital position enjoyed a strong boost from non-organic items.